Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Basilea PharmaceuticaXSWX:BSLN -2.07%61 Return-on-Tangible-Equity is 42.42% as of Dec. 2025, which is 67% below its 10-year median of 130.06. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.71 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,199 Biotechnology companies, Basilea Pharmaceutica ranks better than 93.91% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Basilea Pharmaceutica's annualized net income for the quarter that ended in Dec. 2025 was CHF48.9 Mil. Basilea Pharmaceutica's average shareholder tangible equity for the quarter that ended in Dec. 2025 was CHF115.2 Mil. Therefore, Basilea Pharmaceutica's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 42.42%.
The historical rank and industry rank for Basilea Pharmaceutica's Return-on-Tangible-Equity or its related term are showing as below:
XSWX:BSLN'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 38.66 Med: 130.06 Max: 221.46
Current: 38.81
During the past 13 years, Basilea Pharmaceutica's highest Return-on-Tangible-Equity was 221.46%. The lowest was 38.66%. And the median was 130.06%.
XSWX:BSLN's Return-on-Tangible-Equity is ranked better than 93.91% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs XSWX:BSLN: 38.81
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Basilea Pharmaceutica Return-on-Tangible-Equity Related Terms
Basilea Pharmaceutica Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 42.42% mean?
Basilea Pharmaceutica (XSWX:BSLN) has a Return-on-Tangible-Equity of 42.42% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Basilea Pharmaceutica and its competitors. This is 67% below median its historical median of 130.06. Over the past decade, Basilea Pharmaceutica's Return-on-Tangible-Equity has ranged from 38.66 to 221.46. According to the industry distribution chart, Basilea Pharmaceutica ranks #73 out of 1199 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Basilea Pharmaceutica's Return-on-Tangible-Equity too high?
Basilea Pharmaceutica's current Return-on-Tangible-Equity of 42.42% is 67% below median its 10-year median of 130.06. Over the past 10 years, this metric has ranged from a low of 38.66 to a high of 221.46. Based on the distribution chart, Basilea Pharmaceutica ranks #73 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #73 out of 1199 companies for Return-on-Tangible-Equity. This places Basilea Pharmaceutica in the top 6% of its industry — outperforming the majority of peers. Historically, Basilea Pharmaceutica's own Return-on-Tangible-Equity has ranged from 38.66 to 221.46 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Return-on-Tangible-Equity is 42.42%, which is 67% below median its own 10-year median of 130.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF57.71, compared to a current price of CHF52.00 — trading 9.9% below its estimated fair value. The current Return-on-Tangible-Equity is 42.42%, which is 67% below median its 10-year median of 130.06. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Return-on-Tangible-Equity is 42.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF52.00 is trading 9.9% below its estimated GF Value™ of CHF57.71.
GuruFocus considers Basilea Pharmaceutica to be Modestly Undervalued.
Key valuation signals for XSWX:BSLN:
Return-on-Tangible-Equity: 42.42% (67% below median its 10-year median of 130.06)
GF Value™: CHF57.71 vs. price of CHF52.00 (9.9% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score
Get the complete analysis for XSWX:BSLN
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
